|
Excitotoxins:
The Ultimate Brainslayer
By James South MA
|

WARNING!
THE FOLLOWING ARTICLE IS EXTRACTED FROM THE
COPYRIGHTED INTERNATIONAL ANTIAGING SYSTEMS BULLETIN.
IT
IS INTENDED FOR PRIVATE VIEWING ONLY AND CANNOT BE COPIED
WITHOUT THE WRITTEN PERMISSION OF IAS.
THEY
CAN BE CONTACTED IN GREAT BRITAIN AT THE FOLLOWING;
International
Antiaging Systems (IAS), c/o Les Autelets, Sark GY9 0SF, Great
Britain.
Tel:
+44 870 151 414144 Fax: +44 870 151 414145
E-mail:
ias@antiaging-systems.com
Website:
www.antiaging-systems.com
|
Glutamic acid (also called "glutamate")
is the chief excitatory neurotransmitter in the human and mammalian
brain (1-3). Glutamate (GLU) neurons make up an extensive network
throughout the cortex, hippocampus, striatum, thalamus, hypothalamus,
cerebellum, and visual/auditory system (4). As a consequence, GLU
neurotransmission is essential for cognition, memory, movement and
sensation (especially taste, sight, hearing) (3). GLU and its biochemical
"cousin," aspartic acid or aspartate (ASP), are the two
most plentiful amino acids in the brain (5). ASP is also a major
excitatory neurotransmitter, and ASP can activate neurons in place
of GLU (1,2).
GLU and ASP can be synthesized by
cells from each other, and GLU can be made from various other amino
acids, as well (5). GLU and ASP are both common in foods also. Wheat
gluten is 43% GLU, the milk protein casein is 23% GLU, and gelatin
protein is 12% GLU (5). One of the commonest food additives in the
developed world is MSG (monosodium glutamate), a flavor enhancer.
By 1972 576 million pounds of MSG were added to foods yearly, and
MSG use has doubled every decade since 1948 (2). ASP is one half
of the now ubiquitous sweetener aspartame (NutraSweet®), which
is the basis of diet desserts, low-calorie drinks, chewing gum,
etc. (2,6). Thus, even a superficial look at GLU/ASP in brain chemistry,
foods, and food additive technology indicates a major role for them
in our lives. Without normal GLU/ASP neurotransmission, we would
be deaf and blind mental and behavioural vegetables. Yet ironically
GLU and ASP are the two major excitotoxins out of 70 so far discovered
(1-3,6). Excitotoxins are biochemical substances (usually amino
acids, amino acid analogs, or amino acid derivatives) that can react
with specialized neuronal receptors - GLU receptors - in the brain
or spinal cord in such a way as to cause injury or death to a wide
variety of neurons (1-3, 8-10).
A broad range of chronic neurodegenerative
diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's
chorea, stroke (multi-infarct) dementia, amyotrophic lateral sclerosis
and AIDS dementia are now believed to be caused, at least in part,
by the excitotoxic action of GLU/ASP (1-3, 7-10). Even the typical
memory loss, confusion, and mild intellectual deterioration that
frequently occurs in late middle age/old age may be caused by GLU/ASP
excitotoxity (2,6). Acute diseases and medical conditions such as
stroke brain damage, ischemic (reduced blood flow) brain damage,
alcohol withdrawal syndrome, headaches, prolonged epileptic seizures,
hypoglycaemic brain damage, head trauma brain damage, and hypoxic
(low oxygen) /anoxic (no oxygen) brain damage (e.g. from carbon
monoxide or cyanide poisoning, near-drowning, etc.) are also believed
to be caused, at least in part, by GLU/ASP excitotoxicity (1-3,
7-11). Medical research is focusing more and more on ways to combat
excitotoxicity. A drug called "memantine" which blocks
the main GLU-excitotoxicity site in neurons - the NMDA GLU receptor
(more on this later) - has been used clinically in Germany with
significant success in treating Alzheimer's disease since 1991.
(12). Memantine's NMDA GLU-receptor blocking action has also shown
promise in Parkinson's disease, diabetic neuropathic pain, glaucoma,
HIV dementia, alcohol dementia, and vascular (stroke or arteriosclerosis
- caused dementia (12).
Experimental NMDA - GLU receptor
blockers such as MK-801 (dizocilpine) have also demonstrated the
ability to reduce or eliminate brain damage from acute conditions
such as stroke, ischaemia/hypoxia/anoxia, severe hypoglycaemia,
spinal cord injury and head trauma (1-3). Yet the few available
clinical or experimental excitotoxicity-blocking drugs so far discovered
have significant side effect potential - they may block normal,
essential GLU neurotransmission as well as excitotoxicity (1-3,12).
Fortunately, a review of the basics of GLU excitotoxicity reveals
a host of preventative nutritional/life extension drug strategies
that will minimize or even eliminate the excitotoxic "dark
side" of GLU/ASP.
Excitotoxicity 101:

Figure 1
GLU and ASP are neurotransmitters.
Neurotransmitters are the chemicals that allow neurons to communicate
with and influence each other. Neurotransmitters (NT) serve either
to excite neurons into action, or to inhibit them. NTs are stored
inside neurons in packages called "vesicles." When an
electric current "fires" across the surface of a neuron,
it causes some of the vesicles to migrate to the synapses and release
their NT contents into the synaptic gap [see Figure 1]. The NTs
then diffuse across the gap and "plug in" to receptors
on the receiving neuron. When enough receptors are simultaneously
activated by NTs, the neuron will either "fire" an electric
current all over its surface membrane, if the transmitter/receptors
are excitatory, or else the neuron will be inhibited from electrically
discharging, if the NT/receptors are inhibitory. All the neural
circuitry of our brains work through this interacting "relay
race" of NTs inducing electrical activation or inhibition.
[Figure 1 shows a neuron and the synaptic gap]
GLU receptors are excitatory
- they literally excite the neurons containing them into electrical
and cellular activity. There are 4 main classes of GLU receptors:
the NMDA (N-methyl-D-aspartate) receptor, the quisqualate/ AMPA
receptor, the kainite receptor, and the AMPA metabotropic receptor.
Each of these receptors has a different structure, and has somewhat
different effects on the neurons they excite. The NMDA is the most
common GLU receptor in the brain (13).

Figure 2
The NMDA, kainite and
quisqualate receptors all serve to open ion channels. Looking at
the NMDA receptor diagram [See Figure 2], the NMDA receptor is the
most complex, and had more diverse and potentially devastating effects
on receiving neurons than the others. When GLU or ASP attaches to
the NMDA receptor, it triggers a flow of sodium (Na) and calcium
(Ca) ions into the neuron, and an outflow of potassium (K). It is
this ion exchange that triggers the neuron to "fire" an
electric current across its membrane surface, in turn triggering
a NT release to whatever other neurons the just-fired neuron synaptically
contacts. The kainite and AMPA ion channels primarily permit the
exchange of Na and K ions, and generally cause briefer and weaker
electric currents than NMDA receptors. Thus, when GLU/ASP acts through
kainite/AMPA receptors, it is weakly excitatory, but when GLU/ASP
act through NMDA receptors, they are strongly excitatory (14). NMDA
receptor activation is the basis of long-term potentiation (LTP),
which in turn is the basis for memory consolidation and long-term
memory formation (14). [Figure 2, the NMDA receptors]
Looking at the NMDA
receptor diagram it shows that there are receptor sites for chemicals
other than GLU. The zinc site can be occupied by the zinc ion, and
this will block the opening of the ion channel. The PCP site can
be occupied by the drug PCP ("angel dust"), an animal
tranquilliser; ketamine, an anaesthetic; MK-801, an experimental
NMDA antagonist; or the previously mentioned memantine. When the
PCP is occupied, the opening of the ion channel is blocked, even
when GLU occupies its receptor site (1-3). The mineral magnesium
(Mg) can occupy a site near to, or perhaps identical with, the PCP
site. Magnesium blocks the NMDA channel in a "voltage dependent
manner." This means that as long as the neuron is able to maintain
its normal resting electrical potential of -90 millivolts, the Mg
blocks the ion channel even with GLU in its receptor.
However, if for any
reason (e.g. not enough ATP energy to maintain the resting potential)
the surface membrane electrical charge of the cell drops to -65
millivolts, allowing the neuron to fire, the Mg block is overcome,
and the channel opens, allowing the Na and Ca to flood the neuron
(1-3). After the neuron has fired, membrane pumps then pump the
excess Na and Ca back outside the neuron (15). This is necessary
to return the neuron to its resting, non-firing state. Neurons in
a resting state prefer to keep Ca inside the cell at a level only
1/10,000 of that outside, with Na levels 1/10 as high as outside
the neuron (15). These pumps require ATP energy to function, and
if neuronal energy production is low for any reason (hypoglycaemia,
low oxygen, damaged mitochondrial enzymes, serious B vitamin or
CoQ10 deficiency, etc.), the pumps may gradually fail, allowing
excessive Ca/Na build up inside the cell. This can be disastrous
(1-3).
CA, The excitotoxic
"hit-man":
Normal levels of Ca inside the neuron allow normal functioning,
but when excessive Ca builds up inside neurons, this activates a
series of enzymes, including phopholipases, proteases, nitric oxide
synthases and endonucleases (1,3). Excessive intraneuronal Ca can
also make it impossible for the neuron to return to its resting
state, and instead cause the neuron to "fire" uncontrollably
(1,3). Phospholipase A2 breaks down a portion of the cell membrane
and releases arachidonic acid (AA), a fatty acid. Other enzymes
then convert AA into inflammatory prostaglandin's (PG), thromboxanes
(TX) and leukotrienes (LT), which then damage the cell (1,3). Phospholipase
A2 also promotes the generation of platelet activating factor, which
also increases cell Ca influx by stimulating release of more GLU
(3). And whenever AA is converted to PGs, TXs, and LTs, free radicals,
including superoxide, peroxide and hydroxyl, are automatically generated
as part of the reaction (1-3, 16). Excessive Ca also activates various
proteases (protein-digesting enzymes) which can digest various cell
proteins, including tubulin, microtubule-proteins, spectrin, and
others (1,3). Ca can also activate nuclear enzymes (endonucleases)
that result in chromatin condensation, DNA fragmentation and nuclear
breakdown, i.e. apoptosis, or "cell suicide" (3). Excessive
Ca also activates nitric oxide synthase, which produces nitric oxide
(NO). When this NO reacts with the superoxide radical produced during
inflammatory PG/LT formation, the supertoxic peroxynitrite radical
is formed (3,17). Peroxymtrite oxidizes membrane fats, inhibits
mitochondrial ATP-producing enzymes, and triggers apoptosis (17).
And these are just some of the ways GLU-NMDA stimulated intracellular
Ca excess can damage or kill neurons!
GLU Metabolism:
Excitatory neurons using GLU as their NT normally contain a high
level of GLU (10 millimoles per liter) bound in storage vesicles
(3). The ambient or background level of GLU outside the cell is
normally only about 0.6 micromoles per liter, i.e. about 1/17,000
as much as inside the neuron (3). Excitotoxic damage may occur to
cortex or hippocampus neurons at levels around 2-5 micromoles/liter
(3). Therefore the brain works hard to keep extracellular (synaptic)
levels of GLU low. GLU pumps are used to rapidly return GLU secreted
into synapses back into the secreting neuron, to be restored in
vesicles, or to pump the GLU into astrocytes (glial cells), non-neural
cells that surround, position, protect and nutrify neurons (2,3).
These GLU pumps also require ATP to function, so that any significant
lack of neuronal ATP, for any reason, can cause the GLU pumps to
fail. This then allows extracellular GLU levels to rise dangerously
(2,3). If a GLU neuron dies and dumps its GLU stores into the extracellular
fluid, this can also present a serious GLU-excess hazard to nearby
neurons, especially if GLU pumps are unable to quickly remove the
spilled GLU (3). When GLU is pumped into astrocytes, which is a
major mechanism for terminating its excitatory action, the GLU is
converted into glutamine (GAM). GAM is then released by the astrocytes,
picked up by GLU-neurons, stored in vesicles, and converted back
to GLU as needed (3). This GLU-GAM conversion also requires ATP
energy, however, and this anti-excitotoxic mechanism is also at
risk if cellular energy production is comprises for any reason (3).
Also, excessive free radicals can prevent GLU uptake by astrocytes,
thereby significantly (and dangerously) raising extra cellular GLU
levels (18).
Excitotoxicity:
The background factors:
From this brief discussion of the mechanisms of NMDA-GLU excitotoxicity,
it should be clear that there are 5 main conditions which allow
GLU to shift from NT to excitotoxin:
|
1. inadequate neuronal ATP
levels (whatever the cause);
2. inadequate neuronal levels
of Mg, the natural, non-drug Ca channel blocker;
3. high inflammatory PG/LT
levels (caused by excessive GLU-NMDA stimulated Ca invasion);
4. excessive free radical
formation (caused by PG/LT formation and/or insufficient intracellular
antioxidants/free radical scavengers;
5. inadequate removal of GLU
from the extracellular (synaptic) space back into neurons
or into astrocytes. Addressing each of these conditions will
provide appropriate nutritional/life extension drug strategies
to minimize excitotoxicity.
|
MSG and aspartame:
MSG and aspartame (ASPTM) are 2 of the most widely used food additives
in the modern world. MSG is a flavour enhancer (2), and ASPTM is
an artificial sweetener which is the methyl ester (compound) of
the amino acids phenylalamine and ASP (6). MSG is now used in a
wide variety of processed foods: soups, chips, fast foods, frozen
foods, canned foods, ready-made dinners, salad dressings, croutons,
sauces, gravies, meat dishes, and many restaurant foods (2,7). And
MSG is added not only in the form of pure MSG, but is also added
in more disguised forms, such as "hydrolysed vegetable protein,"
"natural flavour," "spices," "yeast extract,"
"caseinate digest," etc. These additives may contain 20-60%
MSG (2,7). Hydrolyzed vegetable protein is made by boiling down
scrap vegetables in a vat of acid, then neutralizing the mixture
with caustic soda. The resulting brown powder contains 3 excitotoxins:
GLU, ASP and cysteic acid (2).
ASPTM is now the most widely used artificial sweetener, and is the
basis for a whole industry of diet desserts, low-calorie soft drinks,
sugar-free chewing gum, flavoured waters, etc. (2,6). Upon absorption
into the body, ASPTM breaks down into phenylalamine, ASP, and methanol
(wood alcohol), a potent neurotoxin (2,6). Between 1985 and 1988
the U.S. Food and Drug Administration received about 6,000 consumer
complaints concerning adverse reactions to food ingredients. 80%
of these complaints concerned ASPTM!
Excitotoxin research,
The early years:
In 1957, a decade after the widespread introduction of MSG into
the American food supply, two ophthalmology residents, Lucas and
Newhouse, discovered that feeding MSG to newborn mice caused widespread
damage to the inner nerve layer of the retina. Similar, though less
severe destruction was also seen upon feeding MSG to adult mice
(7). In 1969, Dr. John Olney, a neuroscientist and neuropathologist,
repeated Lucas and Newhouse's experiments. His research team discovered
that MSG also caused lesions of the various nuclei of the hypothalamus,
a key brain region that controls secretion of hormones by the pituitary
gland. They also found that the MSG-fed newborn mice became obese,
were short in stature, and suffered multiple hormone deficiencies
(7). By 1990 it was known that GLU is the principal neurotransmitter
of hypothalamic neurons (19), making this key neuroendocrine region
especially sensitive to GLU excitotoxicity. Olney has continued
to be a pioneer in excitotoxin research, and he coined the term
"excitotoxin" in the late 1970s to describe the neural
damage that GLU, ASP, and other similar chemicals can cause (8).
MSG and ASPTM: The
harsh truth:
Defenders of the widespread use of MSG and ASPTM in the world's
food supply rest their belief in the safety of MSG and ASPTM on
one main premise: the protective power of the blood-brain barrier
(BBB) (2,7). It is claimed that even if dietary MSG/ASPTM significantly
raise blood levels of GLU and ASP, the brain will not receive any
extra GLU/ASP due to the protective BBB (2,7). However, there are
many reasons why this claim is false. The animal experiments cited
to back this assertion are usually acute studies - that is, a single
test dose of MSG or ASPTM is given, and no significant elevation
of brain GLU or ASP is found (2). Yet humans eating MSG/ASPTM-laced
foods and drinks don't just get a single daily dose. Those who consume
large quantities of packaged, processed, or restaurant foods frequently
imbibe MSG/ASPTM from breakfast to bedtime snack, even drinking
ASPTM-sweetened flavoured waters in-between meals. Toth and Lajtha
found that when they gave mice and rats ASP or GLU, either as single
amino acids or as liquid diets, over a long period of time (days),
brain levels of these supposedly BBB-excluded excitotoxins rose
significantly - ASP by 61%, GLU by 35% (20).
To further worsen matters,
humans concentrate MSG in their blood 5 times higher than mice from
a comparable dose, and maintain the higher blood level longer than
mice (2). In fact, humans concentrate MSG in their blood to a greater
degree than any other known animal, including monkeys (2). And children
are 4 times more sensitive to a given MSG dose than adults (2).
Although food manufacturers in the U.S. removed pure MSG from their
infant and children's foods in 1969 based on Olney's pioneering
research (and Congressional pressure), they continued to add hydrolysed
vegetable protein to baby foods until 1976, and continue to this
day to add MSG-rich caseinate digest, beef or chicken broth containing
MSG, and "natural flavoring" (a disguised MSG source)
to baby's/children's foods (2). Since excess GLU can affect infants'
and children's brain development, possibly causing "miswiring"
that may lead to attention deficit disorder, autism, cerebral palsy
or schizophrenia, babies and young children are especially vulnerable
to GLU/ASP toxicity (2,9).
It has also been discovered
that there are GLU receptors on the BBB (7). GLU appears to be an
important regulator of brain capillary transport and stability,
and over-stimulation of BBB NMDA receptors through dietary MSG/ASPTM-
induced high blood levels of GLU/ASP may lead to a lessening of
BBB exclusion of GLU and ASP (7). There are also a number of conditions
that may impair the integrity of the BBB, allowing MSG/ASP to seep
through. These include severe hypertension, diabetes, stroke, head
trauma, multiple sclerosis, brain infection, brain tumor, AIDS,
Alzheimer's disease and ageing (2,7). Certain areas of the brain,
called the "circumventricular organs," are not shielded
by the BBB in any case. These include the hypothalamus, the subfornical
organ, the organium vasculosum, the pineal gland, the area postrema,
the subcommisural organ, and the posterior pituitary gland (2).
The research of Dr. M. Inouye, using radioactively labelled MSG,
indicates that MSG may gradually seep into other brain areas following
initial brain entry through the circumventricular organs (2).
Yet another issue that
makes the BBB defence of MSG/ASPTM irrelevant is brain glucose transport.
Glucose is the primary fuel the brain uses to generate its ATP energy.
Continual adequate brain ATP levels are needed, as noted earlier,
to prevent GLU/ASP from shifting from NTs to excitotoxins. Creasey
and Malawista found that feeding high doses of GLU to mice could
decrease the amount of GLU entering the brain by 35%, with even
higher GLU doses leading to a 64% reduction in brain glucose content
(21). Since the brain is unable to store glucose, this GLU effect
alone could be a major basis for promoting excitotoxicity.
MSG/ASPTM defenders also like to point out that GLU and ASP are
natural constituents of food protein, which is generally considered
safe, so why the concern over MSG/ASPTM (2)? Yet there is a key
difference between food-derived GLU/ASP and MSG/ASPTM. Food GLU/ASP
comes in the form of proteins, which contain 20 other amino acids,
and take time to digest, slowing the release of protein bound GLU/ASP
like a "timed-release capsule." This in turn moderates
the rise in blood levels of GLU/ASP. Also, when GLU and ASP are
received by the liver (first stop after intestinal absorption) along
with 20 other aminos, they are used to make various proteins. This
also moderates the rise in blood GLU/ASP levels. Yet when the single
amino MSG is rapidly absorbed (especially in solution - e.g. soups,
sauces and gravies), not requiring digestion, human and animal experiments
show rapid rises in GLU, 5 to 20 times normal blood levels (2).
ASPTM is a dipeptide - a union of 2 aminos- and there exist special
di- and tripeptide intestinal absorption pathways that allow rapid
and efficient absorption (21). The dipeptides are then separated
into free aminos, and as with free MSG there will be a rapid rise
in blood ASP. Thus the characteristics of food-bound GLU/ASP and
MSG/ASPTM are completely different. The phenomenon of excitotoxicity
can occur even if you never use MSG/ASPTM, since neurons can produce
their own GLU/ASP. Nonetheless, given the danger of even slight
rises in synaptic GLU/ASP levels, prudence dictates that dietary
MSG/ASPTM be avoided whenever possible, especially if you fall into
the category of those with weakened BBB previously mentioned - diabetes,
stroke victims, Alzheimer's patients, etc. And once you begin reading
food labels, watching out not only for MSG/ASPTM, but also for "hydrolysed
vegetable protein," "natural flavor," "spice,"
"caseinate digest," "yeast extract," etc., you
will be amazed at how common MSG and ASPTM are in the modern food
supply.
Excitotoxicity,
Stealth development:
It should be emphasized that excitotoxicity can occur in both acute
and chronic (slowly developing) forms. NMDA channel blockers such
as nimodipine and memantine have shown success in blocking the dramatic
change that occurs rapidly after acute excitotoxicity reactions,
as in stroke, asphyxia (lack of oxygen), or head/spinal trauma (2,3,12).
The chronic forms of excitotoxic brain injury will usually occur
much more slowly, and the effects may be subtle until the final
stage of the damage. For example, Parkinson's disease symptoms may
not show up until 80% or more of the nigrostriatal neurons are destroyed,
a partially excitotoxic process that may proceed "silently"
for decades before symptoms present themselves (2).
Similarly, excitotoxin
pioneer Olney has recently shown that there is a long, slow development
of excitotoxic brain damage in Alzheimer's disease that occurs before
the dramatic Alzheimer's symptoms of memory loss, disorientation,
cognitive impairment, and emotional lability arise (10). So you
must not assume that just because you don't notice any obvious symptoms
when you consume MSG/ASPTM-containing foods, there is no excitotoxic
damage occurring.
Excitotoxicity protection,
The program:
As mentioned previously, there are 5 main background factors that
promote the transition of GLU/ASP from NTs to excitotoxins. These
will now be examined, since they provide the rationale for a program
of nutritional supplements/ life extension drugs to combat excitotoxicity.
1. Inadequate neuronal
ATP levels. This factor is one of the 2 chief keys to preventing
excitotoxicity. ATP is the energy "currency" of all cells,
including neurons. Each neuron must produce all the ATP it needs
- there is no welfare state to take care of needy but helpless neurons.
ATP is needed to pump GLU out of the synaptic gap into either the
GLU -secreting neuron or into astrocytes. ATP is needed by atrocytes
to convert GLU into glutamine. ATP is needed by sodium and calcium
pumps to get excess sodium and calcium back out of the neuron after
neuron firing. ATP is needed to maintain neuron resting electric
potential, which in turn maintains the Mg-block of the GLU-NMDA
receptor. With enough ATP bioenergy, neurons can keep GLU and ASP
in their proper role as NTs.
Neurons produce ATP by "burning" glucose (blood sugar)
through 3 interlocking cellular cycles: the glycolytic and Krebs'
cycles, and the electron transport chain (ETC), with most of the
ATP coming from the ETC (22). Various enzyme assemblies produce
ATP from glucose through these 3 cycles, with the Krebs' cycle and
ETC occurring inside mitochondria, the power plants of the cell.
The various enzyme assemblies require vitamins B1, B2, B3 (NADH),
B5 (pantothenate), biotin, and alpha-lipoic acid as coenzyme "spark
plugs" (22). Mg is also required by most of the glycolytic
and Krebs' cycle enzymes as a mineral co-factor (22). The ETC especially
relies on NADH and coenzyme Q10 (Co Q10) to generate the bulk of
the cell's ATP (22). Supplementary sublingual ATP, by supplying
preformed adenosine to cells, can also help in ATP (adenosine triphosphate)
formation (22). Idebenone is a synthetic variant of CoQ10 that may
work better than CoQ10, especially in low oxygen conditions, to
keep ATP production going in the ETC (22). ALCAR (acetyl-l-carnitine)
is a natural mitochondrial molecule that may regenerate aging mitochondria
that are suffering from a lifetime of accumulated free radical damage
(22). Thus the basic pro-energy anti-excitotoxic program consists
of 50-100 mg of B1, B2, B3, B5; 500-10,000 mcg of biotin; 100-300
mg alpha-lipoic acid; 50-300 mg CoQ10; 45-90 mg Idebenone; 10-30
mg sublingual ATP; 500-2000 mg ALCAR; and 300-600 mg Mg; and 5-20
mg NADH. All should be taken in divided doses with meals, except
the NADH, which is taken on an empty stomach.
2. Inadequate neuronal
levels of Mg. Mg is nature's non-drug NMDA channel blocker. Mg is
also essential, as just mentioned, for ATP production, and the small
amount of ATP that can be stored in cells is stored as MgATP. Mg
injections are routinely given to alcoholics going through extreme
withdrawal symptoms (delerium tremens), and alcohol withdrawal is
an excitotoxic process (11). Mg dietary levels in Western countries
are typically only 175-275mg/day (23). Dr Mildred Seelig, a noted
Mg expert, has calculated that a minimum of 8 mg of Mg/Kg of bodyweight
are needed to prevent cellular Mg deficiency (24). This would be
560 mg/day for a 70 kg (154 pound) person. Alcoholics, chronic diuretic
users, diabetics, candidiasis patients, and those under extreme,
prolonged stress may need even more (25). 300-600 mg Mg per day,
taken with food in divided doses, should be adequate for healthy
persons. Excess Mg will cause diarrhoea; reduce dose accordingly
if necessary. Mg malate, succinate, glycinate, ascorbate, chloride
and taurinate are the best supplemental forms.
3. High neuronal levels
of inflammatory prostaglandins (PG), thromboxanes (TX) and leukotrienes
(LT). The excitotoxic process does much of its damage through initiating
excessive production of PGs, TXs, and LTs. Inflammatory PGs and
TXs are produced by the action of cyclooxygenase 2 (COX-2) on arachidonic
acid liberated from cell membranes (16,26). LTs are produced by
lipoxygenases (LOX) (16). Trans-resveratrol is a powerful natural
inhibitor of both COX-2 and LOX (26,27,28).
The bioflavanoid quercetin
is a powerful LOX-inhibitor (27). Curcumin (turmeric extract), rosemary
extract, green tea extract, ginger and oregano are also effective
natural COX-2 inhibitors (26). It is interesting to note that Alzheimer's
disease is in large part an excitotoxicity disease (2,10), and 20
epidemiological studies published by 1998 indicate that populations
taking anti-inflammatory drugs (e.g. arthritis sufferers) have a
significantly reduced prevalence of Alzheimer's disease or a slower
mental decline (26). However, both steroidal and non-steroidal anti-inflammatory
drugs have potentially dangerous side effects, so the natural anti-inflammatory
substances may be a much safer, if slightly less powerful, alternative.
5-20 mg trans-resveratrol 2-3 times daily, 250-500 mg quercetin
3 times daily, and 300-600 mg rosemary extract 2-3 times daily is
a safe, natural anti-inflammatory program.
4. Excessive free radical
formation/inadequate antioxidant status is a major pathway of excitotoxic
damage. Various free radicals, including superoxide, peroxide, hydroxyl
and peroxynitrite, are generated through the inflammatory PG/LT
pathways triggered by excitotoxic intracellular calcium excess.
These free radicals can damage or destroy virtually every cellular
biomolecule: proteins, fatty acids, phospholipids, glycoproteins,
even DNA, leading to cell injury or death (1-3, 16, 17). Free radicals
are also inevitably formed whenever mitochondria produce ATP (22).
Reduced intraneuronal antioxidant defences is a routine finding
in autopsy studies of brains from Alzheimer's and Parkinson's patients
(2). Although vitamins C and E are the two most important nutritional
antioxidants, and brain cells may concentrate C to levels 100 times
higher than blood levels (30), antioxidants work as a team. Free
radical researcher Lester Packer has identified C, E, alpha-lipoic
acid, CoQ10 and NADH as the most important dietary antioxidants
(31,32). Idebenone has also shown great power in protecting various
types of neurons from free radical damage and other excitotoxic
effects. Idebenone is able to protect neurons at levels 30-100 times
less than the vitamin E levels needed to protect neurons from excitotoxic
damage (33-37). One of the many ways excitotoxins damage neurons
is to prevent the intracellular formation of glutathione, one of
the most important cellular antioxidants. The combination of E and
Idebenone provided complete antioxidant neuronal protection in spite
of extremely low glutathione levels caused by GLU excitotoxic action
(33,34). Idebenone has also shown clinical effectiveness in treating
various forms of stroke and cerebrovascular dementia, known to be
caused by excitotoxic damage (38).
Deprenyl is also indicated for prevention of excitotoxic free radical
damage. In a recent study, Mytilneou and colleagues showed that
deprenyl protected mesencephalic dopamine neurons from NMDA excitotoxicity
comparably to the standard NMDA blocker, MK-801 (39). The chief
bodily metabolite of deprenyl, desmethylselegeline, was shown to
be even more powerful than deprenyl itself at preventing NMDA excitotoxic
damage to dopamine neurons (40). Maruyama and colleagues showed
that deprenyl protected human dopaminergic cells from apoptosis
(cell suicide) induced by peroxynitrite, a free radical generated
through NMDA excitotoxic action (3,17). Deprenyl has also been shown
to significantly increase the activity of 2 key antioxidant enzymes,
superoxide dismutase (SOD) and catalase, in rat brain (41). There
is also good evidence that deprenyl, through its MAO-B inhibiting
action, may favourably modulate the polyamine binding site on NMDA
receptors, thereby reducing excitotoxicity (41). A basic anti-excitotoxic
antioxidant program would thus consist of the following: 200-400
IU d-alpha tocopherol; 100-200 mg gamma tocopherol (this form of
vitamin E has recently been shown to be highly protective against
peroxynitrite toxicity, unlike d-alpha E (42)); 100-200 mcg selenium
as selenomethionine (selenium is necessary for the activity of glutathione
peroxidase, one of the most critical intracellular antioxidants);
500-1,000 mg vitamin C 3-5 times daily; 50-100 mg alpha-lipoic acid
2-3 times daily; 50-300mg CoQ10; 5-20 mg NADH (empty stomach); 45
mg Idebenone 2 times daily; 1.5-2 mg deprenyl daily. Note that some
of these are already covered by the energy enhancement program.
Zinc is necessary for
one form of SOD - zinc SOD - and also blocks the NMDA receptor.
However, high levels of neuronal zinc may over activate the quisqualate/AMPA
GLU receptors, causing an excitotoxic action (1,2). Dr Blaylock,
the neurosurgeon author of Excitotoxins (2), therefore recommends
keeping supplementary zinc levels to 10-20 mg daily (2).
5. Inadequate removal
of extracellular (synaptic) GLU. Excessive synaptic GLU/ASP will
keep GLU receptors (NMDA or non-NMDA) overactive, promoting repetitive
neuronal electrical firing, calcium/sodium influx, and resultant
excitotoxicity. Avoiding dietary MSG/ASPTM will help to minimize
synaptic GLU/ASP levels. Keeping neuronal ATP energy maximal through
avoidance of hypoglycaemia (i.e. don't skip meals or practice "starvation
dieting"), combined with the supplemental energy program described
in 1) above, will promote adequate ATP to assist GLU pumps to remove
excess extracellular GLU to astrocytes. Adequate ATP will also promote
astrocyte conversion of GLU to glutamine, the chief GLU removal
mechanism. Adequate ATP will also keep calcium and sodium pumps
active, preventing excessive intracellular calcium build-up. Intracellular
calcium excess itself promotes renewed secretion of GLU into synapses,
in a positive feedback vicious cycle (3).
An enzyme called "GLU
dehydrogenase" (GDH) also helps neurons dispose of excess GLU
by converting GLU to alpha-ketoglutarate, a Krebs' cycle fuel. GDH
is activated by NADH, so taking the NADH recommended in the energy
and antioxidant programs will also promote breakdown of GLU excess.
Excessive levels of free radicals has been shown to inhibit GLU
uptake by astrocytes, the major route for terminating GLU receptor
activation (29), so following the antioxidant program will also
aid in clearing excess synaptic GLU.
In order to maximize
clearance of synaptic GLU, it will also be necessary to avoid use
of the nutritional supplement glutamine (GAM). The health food industry
has promoted GAM use for decades, often in multi-gram quantities.
A 1994 book touts GAM "to strengthen the immune system, improve
muscle mass, and heal the digestive tract" (43). It is true
that many studies do show benefits form short-term, often high dose,
GAM use. It must be remembered, however, that GAM easily passes
the BBB and enters the astrocytes and neurons, where it can be converted
to GLU. And the excitotoxic damage from excess GLU may take a lifetime
to develop to the point of expressing itself as a stroke, Alzheimer's
or Parkinson's disease, etc. But high dose GAM can cause excitotoxic
problems even in the short term. At last year's Monte Carlo Anti-Aging
Conference, I met a man who routinely consumed 20 grams of GAM daily.
He suffered extremely severe insomnia, nervousness, anxiety, racing
mind, and other symptoms of excessive GLU neurotransmission. GAM
supplementation should probably not exceed 1-2 grams daily, if it
is used at all.
Excitotoxins, Final
thoughts and observations:
A 1994 review article referred to excitotoxicity as "the final
common pathway for neurologic disorders" (3). Yet public awareness
of the excitotoxic phenomenon has been slow in coming, even in the
life extension/natural medicine/health food communities. Only one
book has tried to alert the public to the details of how excitotoxins
gradually (or sometimes suddenly) destroy our brains: Blaylock's
1994/1997 Excitotoxins (2). This article has barely scratched the
surface of excitotoxins and their role in our lives. The interested
reader is strongly urged to read Blaylock's book. It is written
by a neurosurgeon, is highly readable and understandable for such
a technical subject, and provides a wealth of practical information
and extensive scientific documentation. Blaylock presents an especially
detailed picture of the role of GLU/ASP excitotoxicity in the development
of Alzheimer's disease, as well as steps to prevent or cope with
Alzheimer's. It makes little sense to pursue other anti-aging strategies,
such as growth hormone, testosterone or estrogen replacement, cardiovascular
fitness exercise, weight loss, etc. while not doing everything possible
to avoid excitotoxicity. As Blaylock points out, in a recent survey
of the elderly, it was learned that the incidence of Alzheimer's
was 3% among the 65 to 74 age group, 18.7% among those 75 to 84,
and 47.2% (!) among those 85 and older (2). The over-85 age group
is the fastest growing age group in the U.S. Anyone who seriously
follows any anti-aging techniques has a real chance of joining that
85-plus age group. But what is the point of reaching 85, only to
end up suffering the terrible physical, mental and emotional deterioration
of Alzheimer's (or Parkinson's, or stroke dementia, etc.)?
Learning about, and doing what is necessary to cope with, the brain's
tendency to excitotoxically "melt down" is the best brain
anti-aging insurance available.
About The
Author:
James South MA, is a biochemist with many years of experience of
working with leading US nutritional companies and he has been responsible
for many unique formulations. He is the author and co-author of
numerous books and today is the Director of Research at International
Anti-Aging Systems.

DISCLAIMER;
ALL INFORMATION IS EDUCATIONAL AND
PROVIDED UNDER IAS TERMS AND CONDITIONS.
IT DOES NOT AND SHOULD NOT REPLACE THE ADVICE OF YOUR PHYSICIAN.

|
|
Article References:
1. Choi, D. (1988) "Glutamate neurotoxicity and diseases
of the nervous system" Neuron 1: 623-34.
2. Blaylock, R. Excitotoxins.
Santa Fe: Health Press, 1997.
3. Lipton, S. &
Rosenberg, P. (1994) "Excitatory amino acids as a final
common pathway for neurologic disorders" NEJM 330: 613-22.
4. Greenamyre, J. &
Porter, R. (1994) "Anatomy and physiology of glutamate
in the CNS" Neurol 44: s7-s13.
5. Braverman, E. et
al. The Healing Nutrients Within. New Canaan: Keats Pub.,
1997.
6. Roberts, H. Aspartame
(NutraSweet®) Is It Safe? Philadelphia: The Charles Press,
1990.
7. Blaylock. R. (2000)
"Excitotoxins: Dangerous Food Additives" Nexus 7
(#4&5), 31-34, 74-75 & 35-40.
8. Whetsell, W. &
Shapira, N. (1993) "Biology of disease. Neuroexcitation,
excitotoxicity and human neurological disease." Lab Invest
68: 372-87.
9. Olney, J. (1989)
"Glutamate, a neurotoxic transmitter" J Child Neurol
4: 218-26.
10. Olney, J. et al
(1997) "Excitotoxic neurodegeneration in Alzheimer disease"
Arch Neurol 54:1234-40.
11. Tsai, G.E. et al
(1998) "Increased glutamatergic neurotransmission and
oxidative stress after alcohol withdrawal" Am J Psychiat
155: 726-32.
12. (2001) "Needless
brain wasting" Life Extension 7 (7): 64-68.
13. Blaylock, Excitotoxins,
p.49.
14. Levitan, I. &
Kaczmarek. The Neuron. NY & Oxford: Oxford Univ. Press,
1997.
15. Guyton, A. &
Hall, J. Textbook of Medical Physiology. Philadelphia: W.B.
Saunders, 2000.
16. Levine, S. &
Kidd, P. Antioxidant Adaptation. S.F.:Biocurrents, 1986.
17. Maruyama, W. et
al (1998) "(-)-Deprenyl protects human dopaminergic neuroblastoma
cells from apoptosis induced by peroxynitrite and nitric
oxide" J Neuronchem 70: 2510-15.
18. Sorg, O. et al (1997)
"Inhibition of astrocyte glutamate uptake by reactive
oxygen species: role of antioxidant enzymes" Mol Med
7: 431-40.
19. Pol, A. et al (1990)
"Glutamate, the dominant excitatory transmitter in neuroendocrine
regulation" Sci 250: 1276-78.
20. Toth, E. & Lajtha,
A. (1981) "Elevation of cerebral levels on nonessential
amino acids in vivo by administration of large doses"
Neurochem Res 6:1309-17.
21. Zaloga, G. (1990)
"Physiologic effects of peptide-based enteral formulas"
Nutr Clin Pract 5: 231-37.
22. South, J. (1999)
"Tired of being tired?" Anti-Aging Bull 4(4): 3-21.
23. Wester, P.o. (1987)
"Magnesium" Am J Clin Nutr 45: 1305-12.
24. Seelig, M. (1964)
"Perspectives in nutrition. The requirement of magnesium
by the normal adult" Am J Clin Nutr 14: 342-90.
25. South, J. (1990)
"Magnesium: the missing link to health" Opt Nutr
Rev 1: 1, 5-8.
26. Newmark, T. &
Schulick, P. Beyond Aspirin. Prescott A2: Hohm Press, 2000.
27. Pace-Asciak, C.
et al (1995) "The red wine phenolics trans-resveratrol
and quercetin block human platelet aggregation and eicosanoid
synthesis: Implicaitons for protection against coronary heart
disease" Clin Chim Acta 235: 207-19.
28. Kimura, Y. et al
(1985) "Effects of stilbenes on arachidonate metabolism
in leukocytes" Biochim Biophys Acta 834: 275-78.
29. Same as ref. 18.
30. Grünewald,
R. (1993) "Ascorbic acid in the brain" Brain Res
Rev 18: 123-33.
31. Packer, L. &
Colman, C. The Antioxidant Miracle. NYC: John Wiley, 1999.
32. Packer, L. &
Tritschler, H. (1996) "Alpha-lipoic acid: the metabolic
antioxidant" Free Rad Biol Med 20: 625-26.
33. Oka, A. et al (1993)
"Vulnerability of oligodendroglia to glutamate: pharmacology,
mechanisms and protection" J Neurosci 13: 1441-53.
34. Murphy, T. et al
(1990) "Immature cortical neurons are uniquely sensitive
to glutamate toxicity by inhibition of cystine uptake"
FASEB J 4: 1624-33.
35. Miyamoto, M. &
Coyle, J. (1990) "Idebenone attenuates neuronal degeneration
induced by intrastriatal injection of excitotoxins" Exp
Neurol 108: 38-45.
36. Miyamoto, M. et
al (1989) "Antioxidants protect against glutamate-induced
cytotoxicity in a neuronal cell line" J Pharmacol Exp
Ther 250: 1132-40.
37. Bruno, V. et al
(1994) "Protective action of idebenone against excitotoxic
degeneration in cultured cortical neurons" Neurosci Lett
178: 193-96.
38. Sekimoto, H. et
al (1985) "Efficacy and safety of CV-2619 (idebenone)
in multiple cerebral infarction, cerebrovascular dementia,
and senile dementia" Ther Res 2:957-72.
39. Mytilineou, C. et
al (1997) "L-Deprenyl protects mesencephalic dopamine
neurons from glutamate receptor-mediated toxicity in vitro"
J Neurochem 68: 33-39.
40. Mytilineou, C. et
al (1997) "L-(-)-Desmethylselegeline, a metabolite of
selegeline [L-(-)-deprenyl], protects mesencephalic dopamine
neurons from excitotoxicity in vitro" J Neurochem 68:
434-36.
41. Gerlach, M. et al
(1996) "Pharmacology of selegeline" Neurol 47 (suppl
3): s137-s145.
42. Christen, S. et
al (1997) "Gamma-tocopherol traps mutagenic electrophiles
such as NO(X) and complements alpha tocopheral: physiologic
implications" Proc Natl Acad Sci USA 94: 3217-22.
43. Shabert, J. &
Ehrlich, N. The Ultimate Nutrient Glutamine. Garden City Park,
NY: Avery, 1994.
|
|